Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service decompression & minimally invasive spine cases in Mississippi: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (250 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 30 | 1,507 | 22% |
| 2020 | 23 | 1,265 | 25% |
| 2021 | 26 | 1,197 |
Laminotomy, laminectomy, interspinous devices; the MIS call point. Professional codes (what the surgeon bills): CPT 63030, 63047, 63020, 63045, 22867; the hospital bills MS-DRG 518, 519, 520.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 74% of the cases CMS names in Mississippi; 12 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Lumbar fusion | 14 | 679−5.9%/yr | −5.9%/yr | 1.80.5× | 0% | 520 in 2030−4.5%/yr |
| Kyphoplasty & vertebroplasty |
Decompression & minimally invasive spine in every state, and its device makers · Every procedure market in Mississippi · Every state · Compare with Texas
| ≈ 740 |
| – |
| 2026 est. | ≈ 730 | – |
| 32% |
| 2022 | 27 | 1,072 | 37% |
| 2023 | 24 | 900 | 42% |
| 2024 | 19 | 811 | 46% |
| 2025 from claims | – | 737 596–866 | 47% |
| 2026 forecast | – | 734 575–922 | 48% |
| 2027 forecast | – | 731 542–966 | 49% |
| 2028 forecast | – | 727 515–1,004 | 50% |
| 2029 forecast | – | 723 492–1,037 | 51% |
| 2030 forecast | – | 719 471–1,067 | 52% |
In 2025, 29% inpatient hospital, 47% hospital outpatient, 24% surgery center. The share outside the hospital has moved +19 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| 7,562−4%/yr |
| −4%/yr |
| 3.3 |
| 15% |
| 8,490 in 2030+1.9%/yr |
| North Carolina | 90 | 3,162−8.5%/yr | −8.5%/yr | 3.1 | 17% | 3,120 in 2030−0.2%/yr |
| Virginia | 64 | 2,968−6.1%/yr | −6.1%/yr | 2.8 | 2% | 3,270 in 2030+1.7%/yr |
| Tennessee | 70 | 2,945−5.3%/yr | −5.3%/yr | 4.0 | 12% | 3,010 in 2030+0.4%/yr |
| Maryland | 71 | 2,940−4.2%/yr | −4.2%/yr | 3.3 | 5% | 3,010 in 2030+0.4%/yr |
| Georgia | 72 | 2,880−6.9%/yr | −6.9%/yr | 3.2 | 7% | 3,140 in 2030+1.5%/yr |
| South Carolina | 56 | 2,163−7.6%/yr | −7.6%/yr | 3.1 | 7% | 2,560 in 2030+2.8%/yr |
| Oklahoma | 44 | 1,608−8.9%/yr | −8.9%/yr | 3.2 | 1% | 1,650 in 2030+0.4%/yr |
| Alabama | 39 | 1,508−11%/yr | −11%/yr | 3.3 | 4% | 1,590 in 2030+0.9%/yr |
| Louisiana | 29 | 1,488−6.6%/yr | −6.6%/yr | 3.5 | 5% | 1,490 in 2030+0.1%/yr |
| Kentucky | 33 | 1,469−9.4%/yr | −9.4%/yr | 3.1 | 1% | 1,500 in 2030+0.4%/yr |
| Arkansas | 30 | 1,254−7.9%/yr | −7.9%/yr | 3.2 | 7% | 1,220 in 2030−0.4%/yr |
| Delaware | 11 | 619+0.2%/yr | +0.2%/yr | 3.5 | 16% | 820 in 2030+4.7%/yr |
| District of Columbia | 9 | 350−0.3%/yr | −0.3%/yr | 5.4 | 8% | 320 in 2030−1.3%/yr |
| West Virginia | 6 | 276−14%/yr | −14%/yr | 1.3 | 0% | 310 in 2030+2.1%/yr |
| 7 |
| 578−8.4%/yr |
| −8.4%/yr |
| 1.50.9× |
| 34% |
| 660 in 2030+2.3%/yr |
| Cervical fusion & disc arthroplasty | 13 | 506−7.3%/yr | −7.3%/yr | 1.30.8× | 24% | 500 in 2030−0.3%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Stryker leads with 59% of company spending on these surgeons in 2025, +58 pts on 2024.
In 2025, 4 companies reported engagement with Mississippi’s surgeons worth $89K in consulting, speaking, meals and travel tied to these products, about $4,692 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.